Treatment sequencing for anemic myelofibrosis
Join us for an informative webinar discussing treatment sequencing for anemic myelofibrosis (MF). This webinar aims to enhance your understanding of the current clinical landscape of MF, optimal treatment sequencing, and key data from recent clinical trials. By attending this session, you will gain insight into the novel therapeutic targets and mechanisms of action in MF and how to implement treatment algorithms in clinical practice. Additionally, there will be a live Q&A session so you can speak directly to our expert panel.
Don't miss out on this opportunity to learn more about treatment sequencing in anemic MF!
This webinar is part of the MPN Hub Clinical Trial Club series, Novel agents for the treatment of advanced myelofibrosis, and is brought to you by the MPN Hub and Scientific Education Support.
Agenda
CME accreditation will be provided by the European Board for Accreditation of Continuing Education for Health Professionals (EBAC). You will receive 1 hour of external CME credit for full attendance of the webinar, including completion of the pre-/post-CME test questions and evaluation.
Welcome and introductions
Current clinical landscape in anemic MF
- Current guidelines
- Momelotinib approval
- Treatment challenges and unmet needs
Optimal treatment sequencing in anemic MF
- When to initiate therapy
- First-line therapy considerations
- Relapsed and refractory disease
Ongoing clinical trials and key data
- NCT03194542 - A phase II study of luspatercept
- Pacritinib (e.g. NCT02055781)
Q&A Session
Evaluation/close
In compliance with EBAC guidelines, all speakers/chairpersons participating in this program have disclosed or indicated potential conflicts of interest which might cause a bias in the presentations. The Organizing Committee/Course Director is responsible for ensuring that all potential conflicts of interest relevant to the event are declared to the audience prior to the CME activities.
Learning objectives
Following this webinar, participants will be able to:
- Describe novel therapeutic targets in anemic MF and explain the mechanisms of action for new agents
- Explain the role of new agents in the therapeutic landscape
- Recall and implement treatment algorithms in clinical practice
Our speakers
Meet our panel of experts
Jean-Jacques Kiladjian
Université Paris Cité
Paris, FR
Angela Fleischman
University of California, Irvine
Irvine, US
About the MPN Hub
The MPN Hub is an open-access online resource, dedicated to providing balanced, credible, and up-to-date medical education in MPN. Our aim is to enhance knowledge in MPN through the multichannel dissemination of global advances related to its classification, diagnosis, treatment, and management.
The MPN Hub shares new data, evidence-based articles, therapy approvals, expert opinions, and international congress coverage to treatment teams and researchers around the world.